Edition:
United States

People: Allergan plc (AGN)

AGN on New York Consolidated

235.94USD
27 May 2016
Change (% chg)

$3.58 (+1.54%)
Prev Close
$232.36
Open
$232.99
Day's High
$236.48
Day's Low
$232.26
Volume
3,055,435
Avg. Vol
4,426,548
52-wk High
$340.34
52-wk Low
$195.50

Summary

Name Age Since Current Position

Paul Bisaro

55 2014 Executive Chairman of the Board

Brenton Saunders

45 2014 President, Chief Executive Officer, Director

Maria Hilado

51 2014 Chief Financial Officer, Executive Vice President

Robert Stewart

47 2014 Chief Operating Officer, Executive Vice President

Karen Ling

51 2014 Chief Human Resource Officer

Jonathon Kellerman

2014 Executive Vice President, Chief Compliance Officer

William Meury

46 2014 Executive Vice President Commercial, North American Brands

James D'Arecca

44 2013 Chief Accounting Officer

Alex Kelly

58 2015 Chief Communications Officer

A. Robert Bailey

51 2014 Chief Legal Officer and Corporate Secretary

Catherine Klema

56 2014 Lead Independent Director

Michael Gallagher

69 2015 Director

Peter McDonnell

57 2015 Director

Nesli Basgoz

57 2014 Independent Director

James Bloem

64 2013 Independent Director

Christopher Bodine

59 2013 Independent Director

Christopher Coughlin

63 2014 Independent Director

Patrick O'Sullivan

73 2013 Independent Director

Ronald Taylor

67 2013 Independent Director

Fred Weiss

73 2013 Independent Director

Biographies

Name Description

Paul Bisaro

Mr. Paul M. Bisaro serves as Executive Chairman of the Board of Actavis PLC. Bisaro had previously served as President and CEO of Actavis plc, and Chairman of the Board, since October 2013. He was named President and Chief Executive Officer and a member of the Company's Board of Directors in 2007. Prior to joining Actavis, Inc., Mr. Bisaro was President, Chief Operating Officer and a member of the Board of Directors of Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company ("Barr"), from 1999 to 2007. Between 1992 and 1999, Mr. Bisaro served as General Counsel of Barr, and from 1997 to 1999 served in various additional capacities including Senior Vice President — Strategic Business Development. Prior to joining Barr, he was associated with the law firm Winston & Strawn and a predecessor firm, Bishop, Cook, Purcell and Reynolds from 1989 to 1992. Mr. Bisaro holds an undergraduate degree in General Studies from the University of Michigan and a Juris Doctor from Catholic University of America in Washington, D.C.

Brenton Saunders

Mr. Brenton L. Saunders serves as President, Chief Executive Officer, Director of the Company. He previously served as Chief Executive Officer and President of Forest and had served as a Director of Forest since 2011. Prior to joining Forest, he served as the Chief Executive Officer and board member of Bausch + Lomb Incorporated from March 2010 until August 2013. Mr. Saunders served as a senior executive with Schering-Plough from 2003 to 2010, most recently as President of Global Consumer Health Care. He also served as Head of Integration for both Schering-Plough's merger with Merck & Co. and for its $16 billion acquisition of Organon BioSciences. Before joining Schering-Plough, Mr. Saunders was a Partner and Head of the Compliance Business Advisory Group at PricewaterhouseCoopers LLP from 2000 to 2003. Prior to that, he was Chief Risk Officer at Coventry Health Care between 1998 and 1999 and a co-founder of the Health Care Compliance Association in 1995. Mr. Saunders began his career as Chief Compliance Officer for the Thomas Jefferson University Health System. He received a B.A. from the University of Pittsburgh, an M.B.A. from Temple University School of Business, and a J.D. from Temple University School of Law.

Maria Hilado

Ms. Maria Teresa Bernas Hilado has been appointed as Chief Financial Officer, Executive Vice President of the Company effective December 8, 2014. Ms. Hilado joins Actavis from PepsiCo, Inc., where she has served as Senior Vice President, Finance and Treasurer since 2009. Prior to PepsiCo, she served as Vice President and Treasurer for Schering-Plough Corporation from 2008 to 2009. Ms. Hilado spent more than 17 years with General Motors Corporation, in a variety of increasingly responsible positions most notably Assistant Treasurer from 2006 to 2008, and previously CFO GMAC Commercial Finance LLC from 2001 to 2005. She also held positions in the capital markets, business development, worldwide funding and pension analysis and overseas financing functions. She began her career with Far East Bank and Trust Company, Manila, Philippines. Ms. Hilado serves on the Board of Directors of H.B. Fuller, and previously served on the Board of Directors of Bausch & Lomb. She earned a Master's in Business Administration from the University of Virginia's Darden School of Business Administration, and a Bachelor of Science in Management Engineering from Ateneo de Manila University in the Philippines.

Robert Stewart

Mr. Robert A. Stewart is Chief Operating Officer, Executive Vice President of Actavis, PLC. Mr. Stewart was appointed President, Global Operations on April 27, 2012. As President, Global Operations, Mr. Stewart was responsible for managing the Company’s Anda, Inc. distribution business, in addition to Global Operations. He had served as Executive Vice President, Global Operations, since August 2010. He joined Watson in November 2009 as Senior Vice President, Global Operations. Prior to joining Watson, Mr. Stewart held various positions with Abbott Laboratories, Inc. from 2002 until 2009 where he most recently served as Vice President, Global Supply Chain. From 2005 until 2008, he served as Divisional Vice President, Quality Assurance and prior to this position served as Divisional Vice President for U.S./Puerto Rico and Latin America Plant Operations as well as Director of Operations for Abbott’s Whippany plant. Prior to joining Abbott Laboratories, Inc., he worked for Knoll Pharmaceutical Company from 1995 to 2001 and Hoffman La-Roche Inc. Mr. Stewart received B.S. degrees in Business Management/Finance in 1994 from Fairleigh Dickinson University.

Karen Ling

Ms. Karen Ling serves as Chief Human Resources Officer of the Company, since July 2014. She previously served as Senior Vice President and Chief Human Resources Officer at Forest Laboratories, Inc. since January 2014. Ms. Ling joined Forest from Merck & Co., Inc., where she served as Senior Vice President, Human Resources, for the company’s Global Human Health and Consumer Care businesses worldwide. Prior to that role at Merck, she was Vice President, Compensation and Benefits. Before Merck, Ms. Ling was Group Vice President, Global Compensation & Benefits at Schering-Plough. She also spent 14 years at Wyeth in various positions of responsibility in human resources as well as in Wyeth Pharmaceutical’s Labour and Employment Department. Prior to joining Wyeth, Ms. Ling practiced corporate law with Goldstein and Manello, P.C. in Boston. Ms. Ling holds a B.A. from Yale University and a J.D. from Boston University School of Law.

Jonathon Kellerman

Mr. Jonathon Kellerman has been appointed as Executive Vice President, Chief Compliance Officer of Actavis PLC., with effect from 22 December 2014. Mr. Kellerman joins Actavis from PwC, where he was a partner in PwC's Pharmaceutical and Life Sciences Advisory practice, responsible for helping lead the firm's Governance, Risk & Compliance practice, including a global team of over 100 diverse professionals. Mr. Kellerman brings extensive experience in compliance and sales and marketing performance improvement, including global anti-bribery/anti-corruption program assessment, design and implementation work; building and implementing effective global compliance programs; managing fraud investigations and remediation activities; re-engineering processes supporting key commercial and R&D business activities and compliance controls; and re-designing how companies engage health care professionals. He has also led major "rapid response" organizational and business process improvement initiatives across multiple business and support functions. Earlier in his career, Mr. Kellerman worked in Healthcare Consulting for Zelenkofske Axelrod and in Research for Blank Rome. Mr. Kellerman is a recognized industry thought leader on the future of compliance strategy, organization and function vis-à-vis a rapidly changing business model and regulatory landscape and has been a frequent contributor to white papers, industry publications and conferences. He has a BA in Sociology from Franklin & Marshall College.

William Meury

Mr. William Meury has served as Executive Vice President Commercial, North American Brands of the Company, since July 2014. He previously served as Executive Vice President, Sales and Marketing, Forest Laboratories, Inc. He joined Forest in 1993 and has held positions in Marketing, New Products, Business Development, and Sales. Most recently, as Senior Vice President, Global Commercial and U.S. Marketing, Mr. Meury oversaw the activities of several departments including Product Management, Market Research, and Commercial Assessments, as well as Forest’s Global Marketing and Early Commercialization groups. Mr. Meury has directed 10 product launches during his tenure at Forest. Before joining Forest, Mr. Meury worked in public accounting for Reznick Fedder & Silverman and in financial reporting for MCI Communications. He has a B.S. in Economics from the University of Maryland.

James D'Arecca

Mr. James C. D'Arecca is Chief Accounting Officer of Actavis PLC. Prior to joining Actavis, Mr. D’Arecca held a similar position at Bausch & Lomb. Prior to joining Bausch & Lomb, Mr. D’Arecca worked for Merck & Co., Inc. where he was Executive Director and Business Development Controller responsible for being the primary liaison between the Controller’s organization and the business development and corporate licensing functions. Prior to joining Merck, Mr. D’Arecca was Executive Director and Assistant Controller at Schering-Plough. Mr. D’Arecca also spent 13 years with PricewaterhouseCoopers as a Certified Public Accountant. Mr. D’Arecca received his MBA from Columbia University and his BS in Accounting from Rutgers University.

Alex Kelly

Mr. Alex Kelly is Chief Communications Officer of Actavis plc. Mr. Mayr has served as Chief Communications Officer of Actavis since April 2012 . He joined Actavis (then Watson) as Senior Vice President, Corporate Affairs in September 2009.

A. Robert Bailey

Mr. Robert D. Bailey serves as Chief Legal Officer and Corporate Secretary of the Company, since July 2014. He previously served from November 2013 to June 2014 as Senior Vice President, Chief Legal Officer, General Counsel and Corporate Secretary of Forest Laboratories, Inc. He previously served from 2007 to 2013 as Executive Vice President, Law, Policy and Communications at Bausch + Lomb. Before joining Bausch + Lomb in 1994, Mr. Bailey was an attorney at Nixon Peabody (formerly Nixon Hargrave Devans & Doyle). Mr. Bailey received his law degree from the University of Minnesota and his undergraduate degree from St. Olaf College in Northfield, MN.

Catherine Klema

Ms. Catherine M. Klema serves as Lead Independent Director of Actavis, PLC. She is currently President of Nettleton Advisors LLC, a consulting firm established by Ms. Klema in 2001. Prior to establishing her firm, Ms. Klema served as Managing Director, Healthcare Investment Banking, at SG Cowen Securities from 1997 to 2001. Ms. Klema also served as Managing Director, Healthcare Investment Banking, at Furman Selz LLC from 1994 until 1997, and was employed by Lehman Brothers from 1987 until 1994. Ms. Klema served as a director of Pharmaceutical Product Development, Inc., a global contract research organization, from 2000 to 2011. In March 2012, Ms. Klema was appointed to the Montefiore Medical Center Board of Trustees.

Michael Gallagher

Dr. Michael R. Gallagher serves as Director of Actavis Public Limited Company. Dr. McDonnell served on the Allergan, Inc. Board of Directors from 1998 until our acquisition of Allergan in March 2015, and served as its Lead Independent Director and Chair of the Organization and Compensation Committee. In 2004, Mr. Gallagher retired as Chief Executive Officer and as a Director of Playtex Products, Inc. Prior to joining Playtex in 1995, Mr. Gallagher was Chief Executive Officer of North America for Reckitt & Colman plc; President and Chief Executive Officer of Eastman Kodak’s subsidiary, L&F Products; President of the Lehn & Fink Consumer Products Division at Sterling Drug, General Manager of the Household Products Division of the Clorox Company, and Brand Manager of The Procter & Gamble Company. Mr. Gallagher is a member and past Chairman of the Board of Advisors of the Haas School of Business, University of California, Berkeley.

Peter McDonnell

Dr. Peter J. McDonnell, M.D. serves as Director of Actavis Public Limited Company. Dr. McDonnell was appointed to the Allergan Board in 2013, and served on the Corporate Governance and Compliance Committee and the Science and Technology Committee. Dr. McDonnell is the Director and William Holland Wilmer Professor of the Wilmer Eye Institute of the Johns Hopkins University School of Medicine since 2003. Dr. McDonnell also serves as the Chief Medical Editor of Ophthalmology Times since 2004, and has served on the editorial boards of numerous ophthalmology journals. Dr. McDonnell also served as the Assistant Chief of Service at the Wilmer Institute from 1987 to 1988. He served as a consultant to the United States Department of Health and Human Services in 1996. Dr. McDonnell served as a full-time faculty at the University of Southern California from 1988 until 1999, where he advanced to the rank of professor in 1994. Dr. McDonnell is an international leader in corneal transplantation, laser refractive surgery and the treatment of dry eye. Dr. McDonnell's research interests include the causes and correction of refractive error, corneal wound healing and microbial keratitis. In 1999, Dr. McDonnell was named the Irving H. Leopold Professor and Chair of the Department of Ophthalmology at the University of California-Irvine . He is the recipient of research grants from the National Eye Institute, Research to Prevent Blindness, and other funding agencies. He has published over 250 scientific articles and holds four patents. The American Academy of Ophthalmology honored him with the Honor Award in 1991 and the Senior Achievement Award in 2001. In 2003, he received the Alcon Research Institute Award. Dr. McDonnell has served on the editorial boards of six ophthalmology journals. Dr. McDonnell is a member of many professional ophthalmology and medical societies.

Nesli Basgoz

Dr. Nesli Basgoz, M.D. serves as Independent Director of the Company. Dr. Basgoz has served as a Director of Forest since 2006. She is the Associate Chief for Clinical Affairs, Division of Infectious Diseases at Massachusetts General Hospital (MGH) and serves on the hospital's Board of Trustees. In addition, Dr. Basgoz is an Associate Professor of Medicine at Harvard Medical School. Previously, Dr. Basgoz served as Clinical Director in the Infectious Diseases Division of MGH for six years. Dr. Basgoz earned her M.D. Degree and completed her residency in internal medicine at Northwestern University Medical School. She also completed a fellowship in the Infectious Diseases Division at the University of California at San Francisco. She is board certified in both infectious diseases and internal medicine.

James Bloem

Mr. James H. Bloem is an Independent Director of Actavis PLC. He previously served as a member of the Warner Chilcott plc (“Warner Chilcott”) Board of Directors since 2006 and was a member of the board of one of Warner Chilcott’s predecessor companies from 1996 to 2000. Mr. Bloem retired on December 31, 2013, after 13 years as Senior Vice President, Chief Financial Officer and Treasurer of Humana Inc. (“Humana”), one of the nation’s largest health benefit companies. He joined Humana in 2001 and had responsibility for all of the Humana’s accounting, actuarial, analytical, financial, tax, risk management, treasury and investor relations activities. Mr. Bloem also serves as Chairman of the Board of Directors of ResCare, Inc., as well as a director of Rotech Healthcare, Inc.

Christopher Bodine

Mr. Christopher W. Bodine serves as an Independent Director of Actavis, PLC. since October 2013. Mr. Bodine retired from CVS Caremark in January 2009 after 24 years with CVS. Prior to his retirement, Mr. Bodine served as President, Healthcare Services of CVS Caremark Corporation, where he was responsible for strategy, business development, trade relations, sales and account management, pharmacy merchandising, marketing, information technology and Minute Clinic. Prior to the merger of CVS Corporation and Caremark Rx, Inc. in March 2007, Mr. Bodine served for several years as Executive Vice President — Merchandising and Marketing of CVS Corporation. Mr. Bodine is active in the pharmaceutical industry, having served on a number of boards and committees, including the Healthcare Leadership Council, RI Quality Institute, National Retail Federation, National Association of Chain Drug Stores (NACDS), and the NACDS Pharmacy Affairs and Leadership Committees. Mr. Bodine also currently serves as a director with Nash Finch.

Christopher Coughlin

Mr. Christopher J. Coughlin is an Independent Director of the Company. Mr. Coughlin has served as a Director of Forest since 2011. He served as an advisor to Tyco International from 2010 until September 30, 2012, and was Executive Vice President and Chief Financial Officer of Tyco from 2005 to 2010. During his tenure, he played a central role in the separation of Tyco into five independent, public companies and provided financial leadership surrounding major transactions, including the $2 billion acquisition of Broadview Security, among many other responsibilities and accomplishments. Prior to joining Tyco, he worked as the Chief Operating Officer of the Interpublic Group of Companies from June 2003 to December 2004, as Chief Financial Officer from August 2003 to June 2004 and as a director from July 2003 to July 2004. Previously, Mr. Coughlin was Executive Vice President and Chief Financial Officer of Pharmacia Corporation from 1998 until its acquisition by Pfizer in 2003. Prior to that, he was Executive Vice President of Nabisco Holdings and President of Nabisco International. From 1981 to 1996 he held various positions, including Chief Financial Officer at Sterling Drug. Mr. Coughlin is currently serving as the lead independent director on the board of Dun & Bradstreet, where he is a former member of the Audit Committee, chairs the Board Affairs Committee and is a member of the Compensation and Benefits Committee. He also serves on the board of Covidien plc, where he is Chair of the Compliance Committee and a member of its Transaction Committee. In addition, Mr. Coughlin previously served on the boards of the Interpublic Group of Companies, Monsanto Company and Perrigo Company. Mr. Coughlin has a B.S. in accounting from Boston College.

Patrick O'Sullivan

Mr. Patrick J. O'Sullivan is an Independent Director of Actavis, PLC. He has served as a Director of Warner Chilcott since 2009. Prior to his retirement in 2006, Mr. O’Sullivan served in positions of increasing responsibility with LEO Pharma A/S (“LEO”) for more than 30 years, most recently as the Chief Executive Officer of LEO Pharma Ireland and as a director of LEO. He also served as a director of LEO Pharmaceuticals Ltd. UK, LEO Pharma SA France and The LEO Foundation. Mr. O’Sullivan is a registered pharmacist, a member and honorary fellow of the Pharmaceutical Society of Ireland and a Knight of the Order of the Dannebrog. Currently, Mr. O’Sullivan is a pharmaceutical business consultant and serves on the Board of Directors of Amarin Corporation plc, where he is a member of the audit committee, nominating committee and corporate governance committee.

Ronald Taylor

Mr. Ronald R. Taylor serves as an Independent Director of Actavis, PLC. Mr. Taylor is the President of Tamarack Bay, LLC, a private consulting firm. He has been a director of Red Lion Hotels Corporation, a hotel operating company, since 1998 and a director of ResMed Inc., a medical device manufacturer, since 2005. Prior to forming Tamarack Bay, Mr. Taylor was a general partner of Enterprise Partners Venture Capital, a venture capital firm, from 1998 until 2001.

Fred Weiss

Mr. Fred G. Weiss serves as an Independent Director of Actavis, PLC. Mr. Weiss served as a member of Actavis, Inc.’s Board of Directors since 2000 and joined our Board of Directors in October 2013. Mr. Weiss is currently the managing director of the consulting firm FGW Consultancy LLC and was previously the managing director of FGW Associates, Inc., a position he held since 1997. Prior to that he served as an executive for Warner-Lambert for nearly 20 years, most recently as Vice President, Planning, Investment and Development. Mr. Weiss is also an Independent Vice-Chairman of the Board and Chairman of the Audit Committee of numerous BlackRock-sponsored mutual funds. In this capacity, and pursuant to BlackRock’s policies, Mr. Weiss has oversight responsibility for finance and accounting matters, and has no responsibility for, or discretion concerning, any of BlackRock’s equity investment decisions. Additionally, Mr. Weiss has been a Director of the Michael J. Fox Foundation for Parkinson’s Research since 2000 and serves as the Chair of the Finance Committee.